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Chronic progressive HIV-1 infection is associated with
elevated levels of myeloid-derived suppressor cells
Thomas Vollbrechta, Renate Stirnera, Amanda Tufmanb, Julia Roidera,
Rudolf M. Huberb, Johannes R. Bognera, Andreas Lechnera, Carole
Bourquina,c and Rika Draenerta
Objectives: Myeloid-derived suppressor cells (MDSC) have been described as sup-
pressors of T cell functions in many tumor models. However MDSC in HIV-1 infection
have not been studied to date. As impaired T cell function is a hallmark of chronic
progressive HIV-1 infection, we hypothesized that MDSC also play a role here.
Methods: Surface staining and FACS analysis were performed on freshly isolated PBMC
of HIV-infected individuals and compared to healthy controls and individuals with lung
carcinoma. MDSC of late-stage HIV-infected subjects were isolated using magnetic
beads and co-cultured with the respective CD8 T cells for evaluation of proliferative
capacity.
Results: We found that chronically HIV-infected HAART-naı¨ve individuals had sig-
niﬁcantly higher CD11bþCD14-CD33þCD15þ MDSC levels than healthy controls
(p¼0.01). MDSC frequencies showed a positive correlation with viral load (r2¼0.24,
p¼0.0002) and a negative correlation with CD4 count (r2¼0.29, p<0.0001).
Initiation of HAART led to a rapid drop in MDSC levels. MDSC from HIV-infected
progressors restricted the proliferative capacity of CD8 T cells from healthy donors and
of Gag/Nef-speciﬁc CD8 T cells from HIV-controllers in vitro. Furthermore
CD11bþCD14-CD33þCD15þ MDSC induced the expansion of
CD4þCD25þFoxP3þ regulatory T cells when co-incubated with PBMC from con-
trollers in vitro.
Conclusion: We conclude that chronic uncontrolled HIV-infection is associated with
elevated levels of MDSC which potentially contribute to the impaired T cell responses
characteristic for the progressive disease stage.
Keywords: cancers, CD8 T cell function, cellular immunity, MDSC, progressive
HIV infection
aMedizinische Klinik und Poliklinik IV, Klinikum der LMU, Munich, Germany, bMedizinische Klinik und Poliklinik V, Klinikum
der LMU, Munich, Germany, and cDepartment of Medicine, University of Fribourg, Fribourg, Switzerland.
Correspondence to Rika Draenert, MD, Medizinische Klinik und Poliklinik IV, Klinikum der LMU, Pettenkoferstr. 8a, 80336
Mu¨nchen
Tel: +49 89 5160 3573; fax: +49 89 5160 3593; e-mail: rika.draenert@med.uni-muenchen.de

Published in "$,'6)±)"
which should be cited to refer to this work.
ht
tp
://
do
c.
re
ro
.c
h
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Introduction
In the natural course of HIV infection, viremia is
controlled by the majority of infected subjects for a
certain time. However loss of control almost always
occurs at some point [1]. HIV-speciﬁc CD8 T cells are an
important component of the adaptive immune response
against HIV, yet these cells become ineffective in most
chronically infected individuals [2,3]. The reasons for this
change in effectiveness are not completely understood
so far.
Myeloid-derived suppressor cells (MDSC) accumulate in
various malignant diseases and were shown to exert
suppressive regulatory functions especially on T cells [4–
6]. In the mouse model MDSC are deﬁned by the
expression of the markers CD11b and Gr1 [5]. Lacking
the marker Gr1, MDSC in humans are less well deﬁned.
There are mainly two different phenotypes that have been
described in cancer patients: CD11bþCD14-
CD33þCD15þ [7,8] and CD14þHLA-DR-/low [9,10].
We hypothesized that MDSC also contribute to T cell
dysfunction in chronic progressive HIV infection,
analogous to what is seen in cancer. We therefore
assessed MDSC frequencies in HIV infected subjects of
various disease stages in comparison to healthy controls.
Additionally we examined MDSC function of HIV
infected individuals in vitro.
Methods
Study subjects
97 individuals participated in the study after signing
informed consent. The study was approved by the
Institutional Review Board of the Ludwig-Maximilians-
Universita¨t, Munich. The study subjects were divided
into the following groups (supplementary digital content
S1): 16 healthy controls; 20 HIV-infected subjects on
highly active antiretroviral treatment (HAART) with
undetectable viral load (VL;< 50 cp/ml) for at least 2
years; 49 HIV-infected HAART-naı¨ve subjects (CD4
counts: 422/ml, range 16–1237; VL: 11,532 cp/ml, range
59–570,156 cp/ml; two subjects were HCV co-infected),
4 HIV-infected subjects with a failing salvage HAART
without further treatment options and 8 subjects with
advanced non-small cell lung carcinoma (NSCLC) as
positive controls. 7 of the 49 HAART-naı¨ve subjects were
reassessed6 weeks after starting HAART. HIV-infected
individuals with proven or suspectedmalignancy based on
clinical, biochemical or radiological ﬁndings were
excluded from the study.
Cell isolation and separation
PBMC were isolated from freshly obtained blood by
Ficoll density gradient centrifugation. For isolation of
CD11bþCD14- MDSC, PBMC were puriﬁed by a
negative selection of CD14þ cells followed by a positive
selection of CD11bþ cells using magnetic microbeads
(Stemcell Technologies, France) according to manufac-
turer’s instructions. Purity for bead-isolated
CD11bþCD14-CD33þCD15þ MDSC was 60 -
96%. MDSC-depleted PBMC contained 0.7–
4.0% MDSC.
Flow cytometry analysis
Extracellular staining with ﬂuorescent antibodies was
performed as described previously [11]. The following
antibodies were used: CD14-APC, CD11b-FITC,
CD33-PE, CD15-PerCP, HLA-DR-PerCP, CD38-PE,
CD25-FITC, CD8-PerCP, CD4-APC (Biolegend,
Germany), CD38-PE (BD, Germany), IL4Ralpha-PE
and isotype control (R&DSystems, Germany). Intra-
cellular staining with anti-FoxP3-PE (Biolegend) was
performed using the FoxP3 staining buffer set (eBios-
ciences, USA) (as described [12]). Cells were collected on
a FACSCalibur (BD, Germany). Data was analyzed using
FlowJo software (TriStar, USA). For gating strategies, see
supplementary digital content S2. As monocyte frequen-
cies vary widely in subjects with a chronic viral infection,
we expressed MDSC as percentage of PBMC.
Mixed lymphocyte reaction and proliferation
assays
Allogeneic PBMC from healthy controls or from HIV
controllers were labeled with CFSE as described [13].
They were then stimulated with PHA (1.25mg/ml;
healthy controls) or a pool of Gag/Nef overlapping
peptides (100mg/ml; HIV controllers) and incubated
alone, with bead-isolated MDSC or with study subject’s
PBMC depleted of MDSC (ratio¼ 2:1) in RPMI media
with 10%FCS (PAA, Austria). After 72 – 96 hours, cells
were stained for CD8-PerCP (Biolegend) and analyzed.
For analysis of regulatory T cell frequencies, cells were
stained for CD4, CD25 and FoxP3 after co-incubation.
Statistical analysis
GraphPad Prism Version 5 was used to analyze data.
Mann-Whitney tests were used to compare groups and
linear regression analysis for correlations. Paired t test was
used for paired comparisons. A p-value <0.05 was
considered statistically signiﬁcant.
Results
CD11bRCD14-CD33RCD15R MDSC are
associated with chronic progressive HIV-1
infection
To determine if MDSCmight play a role in chronic HIV-
1 infection, we compared MDSC frequencies in HIV-
infected individuals to those in healthy controls and to
subjects with advanced NSCLC. We found that HIV-
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infected HAART-naı¨ve individuals had signiﬁcantly
higher CD11bþCD14-CD33þCD15þ MDSC fre-
quencies than healthy controls (p¼ 0.01; Fig. 1a).
We next assessed whether there was an association of
MDSC levels with different stages of HIV infection. As
MDSC levels of HAART-naı¨ve progressors and subjects
with failure of salvage regimen were comparable
(Fig. 1d), we combined the two groups for this analysis.
Controllers (deﬁned as VL<5,000cp/ml; HAART-naı¨ve)
on average had signiﬁcantly lower MDSC frequencies
than individuals with progressive disease (deﬁned as
VL>50,000 cp/ml; p¼ 0.0004; Fig. 1b). Likewise sub-
jects with a CD4 count >500/ml (HAART-naı¨ve) had
signiﬁcantly less MDSC than individuals with a CD4
count <250/ml (Fig. 1b; p¼ 0.0001). MDSC levels of
individuals with medium viral load (5000 – 50,000 cp/
ml) and medium CD4 count (250 – 500/ml) were not
signiﬁcantly different from those of controllers (Fig. 1b).
When looking at all subjects however, there was a
statistically signiﬁcant positive correlation of MDSC
frequencies with VL (Fig. 1c; r2¼ 0.24, p¼ 0.0002) and a
negative correlation with CD4 count (Fig. 1c; r2¼ 0.29,
p<0.0001). In addition MDSC levels correlated signiﬁ-
cantly with immune activation, measured as CD38
expression, on bulk CD8 T cells (r2¼ 0.23, p¼ 0.02; data
not shown) and on HIV-speciﬁc CD8 T cells (r2¼ 0.35,
p¼ 0.002; Fig. 1e).
We then asked the question whether effective HAART
affects the MDSC level. We found lower frequencies of
MDSC in subjects on HAARTwith undetectable VL for
at least 2 years compared to HAART-naı¨ve individuals
with VL>5000 cp/ml (Fig. 1d; p¼ 0.004). Seven of the
HAART-naı¨ve individuals could be studied again after
initiation of HAART. This analysis showed that HAART
led to a rapid drop of MDSC levels (Fig. 1d; p¼ 0.003).
There was no difference in MDSC levels between
subjects on effective HAARTand spontaneous controllers
(deﬁned as VL<5,000cp/ml; HAART-naı¨ve; p¼ 0.58;
Fig. 1d).
Taken together we found that CD11bþCD14-
CD33þCD15þ MDSC are associated with high viral
loads and poor CD4 status in chronic HIV infection.
Another potential phenotype of human MDSC is
CD14þHLA-DR-/low. Such cells
(CD11bþCD14þHLA-DRlowCD33þ) have recently
been described in individuals with chronic HCV
infection [14]. We examined levels of
CD11bþCD14þHLA-DR-/low MDSC in a subgroup
of the HAART-naı¨ve group and in the group on effective
HAART. We did not ﬁnd a positive correlation with VL
in the HAART-naı¨ve subgroup (r2¼ 0.0004, p¼ 0.95;
data not shown). Neither was there a statistically
signiﬁcant difference between HAART-naı¨ve subjects
and individuals on HAART (p¼ 0.64; data not shown).
CD11bRCD14-CD33RCD15R MDSC in HIV-
infected individuals express IL4Ralpha and
impair the proliferative capacity of CD8 T cells
of healthy donors
Tumor-derived MDSC with suppressor function have
been described to express IL4Ralpha [15].
CD11bþCD14-CD33þCD15þ MDSC of our cohorts
also expressed IL4Ralpha suggesting suppressor activity
(supplementary digital content S3).
To further characterize MDSC function in progressive
HIV-infection, we tested for their suppressive activity on
intact CD8 T cells directly ex vivo. Bead-isolated MDSC
of 6 different HIV-infected progressors led to signiﬁcantly
reduced proliferation of PHA-stimulated CD8 T cells of
healthy donors (p¼ 0.004; Fig. 2b) and Gag/Nef-peptide
stimulated CD8 T cells of HIV controllers (p¼ 0.004;
Fig. 2c) in co-culture experiments compared to
incubation with progressors’ MDSC-depleted PBMC.
The latter did not signiﬁcantly alter proliferation
compared to the controls where no cells of HIV-infected
individuals were added.
MDSC levels correlated highly signiﬁcantly with the
frequency of CD4þCD25þFoxP3þ regulatory T cells
(Tregs) in a subgroup of the 49 HAART-naı¨ve individuals
(r2¼ 0.54, p<0.0001; Fig. 2d) directly ex vivo. This
correlation was even stronger than the correlation
between Treg levels and viral load (r2¼ 0.31,
p¼ 0.006; data not shown). Hence we assessed Tregs
in co-incubation experiments. Incubation of PBMC of
HIV controllers with MDSC of progressors led to
signiﬁcantly increased Treg frequencies compared to
incubation of those cells with MDSC-depleted PBMC of
progressors (p¼ 0.0008; Fig. 2e).
CD11bþCD14-CD33þCD15þ MDSC of HIV
infected individuals are of suppressive function shown
by the expression of IL4Ralpha and the reduction of
proliferative capacity of bulk and HIV-speciﬁc CD8 T
cells. Induction of Treg frequencies is therefore proposed
to be one mechanism by which MDSC exert their
suppressive function.
Discussion
MDSC have been described in various malignant diseases
and sepsis as inhibitory regulators of T cells [6,16]. Here
we show for the ﬁrst time that CD11bþCD14-
CD33þCD15þ MDSC can be found to be elevated
in progressive HIV infection and also proof their
suppressive function on CD8 T lymphocytes.
As comparison we used individuals with advanced
NSCLC. NSCLC and renal cell carcinoma are those
malignancies where CD11bþCD14-CD33þCD15þ
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Fig. 1. CD11bRCD14-CD33RCD15R MDSC frequencies in chronic HIV infection. (a) Comparison between healthy controls
(HC), HIV-infected HAART-naı¨ve individuals (HIV untreated)(p¼0.01; Mann-Whitney-Test) and individuals with non-small cell
lung carcinoma (NSCLC). (b) Left: Comparison between low (<5000cp/ml), medium (5000 – 50,000 cp/ml) and high (>50,000 cp/
ml) viral load ofHAART-naı¨ve subjects and individuals with failing salvage regimen (p¼ 0.0004 and p¼0.0003 respectively;Mann-
Whitney-Test). Right: Comparison between high (>500/ml), medium (250 – 500/ml) and low (<250/ml) CD4 counts (p¼0.0001 and
p< 0.0001 respectively; Mann-Whitney-Test). (c) Correlations between MDSC levels and VL (r2¼0,24, p¼0.0002; linear
regression; left) and CD4 count (r2¼0,29, p<0.0001; linear regression; right). (d) Left: Comparison between HIV-infected
HAART-naı¨ve individuals (¼progressor, VL>5000cp/ml), subjects with failing salvage regimen (¼failure), subjects on effective
HAART (¼HAART) and spontaneous controllers (¼controllers, VL< 5000cp/ml). p¼0.004 for group 1 and 3, Mann-Whitney-Test.
Right: Intra-individual comparison before HAART start and6weeks after effective HAART (p¼ 0.003, paired t test). (e) Correlation
between HIV-speciﬁc CD8þCD38þ T cell frequencies and MDSC levels (r2¼ 0.35, p¼0.002; linear regression).
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Fig. 2. Proliferative capacity of CD8 T cells and regulatory T cell frequencies. (a) Representative histograms of CFSE proliferation
assays of PHA-stimulated CD8 T cells of healthy control (HC). MDSC-depleted PBMC¼PBMC of HIV-infected progressor
depleted of MDSC. MDSC¼ bead-isolated MDSC of HIV-infected progressor. (b) Proliferation of PHA-stimulated CD8 T cells of
healthy controls incubated with MDSC-depleted PBMC or MDSC of HIV-progressors (p¼0.004, paired t test). (c) Proliferation of
Gag/Nef-stimulated CD8 T cells of HIV-controllers incubated with MDSC-depleted PBMC or MDSC of progressors (p¼0.004,
paired t test). (d) Correlation between CD4þCD25þFoxP3þ regulatory T cell frequencies andMDSC levels (r2¼0.54, p<0.0001;
linear regression). (e) CD4þCD25þFoxP3þ regulatory T cell frequencies in PBMC of controller after incubation with MDSC-
depleted MDSC or MDSC of HIV progressor (p¼0.0008; paired t test).
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MDSC have been characterized in most detail [7,8]. The
median level of MDSC in NSCLC was higher than in
untreated HIV infection not selected for disease status.
Comparing NSCLC patients with HIV-infected pro-
gressors with very advanced disease status, the difference
becomes less apparent. Disease status seems to be an
important factor for the existence of MDSC. This is also
reﬂected in the correlation of MDSC levels with well
deﬁned clinical markers of HIV infection – viral load and
CD4 count.
Initiation of HAART resulted in a prompt reduction of
MDSC frequencies. In addition subjects on effective
HAART had MDSC levels comparable to HIV-
controllers and healthy controls. Therefore HIV viremia
seems to be a direct inducer of MDSC. This and other
possible mechanisms by which these cells are induced
should be the goal of future studies.
Recently it has been shown that hepatitis C virus is an
inducer of MDSC with a different phenotype [14]. We
were not able to ﬁnd differences between various disease
stages in HIV infection for this phenotype. However in
the report by Tacke et al., PBMC of only 5 subjects with
HCV infection were studied directly ex vivo – as we did
with our subjects. Clinical data, e.g. viral load, for these
subjects were not mentioned. A more detailed analysis
with the same method is necessary to ﬁnally compare the
two ﬁndings.
When testing for the suppressive capacity of MDSC,
proliferation of the target cell is often used as read-out.
Loss of proliferative capacity of T cells has been described
as an effect of human MDSC in hepatocellular carcinoma
[10] and renal cell carcinoma [8] and of murine MDSC in
mouse tumor models [17]. In addition, the expression of
IL4Ralpha has been associated with suppressive function
of MDSC in mice [18] and humans [15]. Therefore we
assume that the MDSC population isolated from HIV
progressors is of suppressive function. As one mechanism
by which MDSC exert their suppressive function, the
induction of regulatory T cells has been proposed [10].
We conﬁrmed this for HIV-derived MDSC in co-
incubation experiments. The relevance of this ﬁnding is
also stressed by the observation that the correlation
between Tregs and MDSC was stronger than the
correlation between Tregs and viral load. Nevertheless
we expect additional mechanisms of action to be used by
MDSC in HIV infection which should be assessed in
future studies.
In summary this is the ﬁrst report of an association of
elevated CD11bþCD14-CD33þCD15þ MDSC levels
with chronic progressive HIV-1 infection. As impaired
CD8 T cell function is a hallmark of progressive HIV
infection, reducing MDSC production or function could
potentially become an adjunct therapeutic approach in
this disease stage.
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